Evidence of Damages to Prove Medical Expenses in Personal Injury or Wrongful Death Actions:
SB 1520 would revise Florida’s rules for proving medical-expense damages in personal injury and wrongful death cases by expanding and clarifying what evidence courts may consider for both past and future medical treatment. The bill amends section 768.0427, Florida Statutes, to specify categories of admissible evidence tied to the claimant’s insurance status, Medicare or Medicaid reimbursement rates, letters of protection, and amounts billed for medically necessary treatment. For claimants with private health coverage, the bill allows evidence of what the insurer would have paid, plus the claimant’s share of costs. For claimants without coverage, or with Medicare/Medicaid coverage, it sets a benchmark of 120% of the Medicare reimbursement rate, or 170% of the Medicaid rate if no Medicare rate applies.
The bill also addresses situations involving letters of protection, including cases where a provider transfers the right to receive payment to a third party, and allows evidence of what that third party paid or agreed to pay. It further provides that evidence of reasonable amounts billed for medically necessary treatment or services may be used to prove damages. The changes apply to both unpaid past medical charges and anticipated future medical expenses, and the act would take effect July 1, 2025.
If enacted, SB 1520 would alter Florida’s evidentiary standards in tort cases by narrowing and specifying the types of proof admissible to establish medical damages, particularly for plaintiffs seeking recovery of past and future medical expenses. It would affect section 768.0427, Florida Statutes, and would likely influence litigation strategy, expert testimony, settlement valuation, and the calculation of damages in personal injury and wrongful death actions. The bill’s benchmarks based on insurance payments and Medicare/Medicaid reimbursement rates would be especially relevant to claimants, health care providers, insurers, and defendants in civil liability cases.
The available context shows no recorded committee transcript or vote history, and the bill ultimately died in Judiciary. Based on the text alone, the measure appears to reflect a policy preference for more standardized and objective evidence of medical damages, which may appeal to supporters seeking predictability and limits on inflated medical billing. At the same time, the absence of recorded debate means there is no documented public sentiment in the provided materials beyond the bill’s failure to advance.
The main points of contention likely involve how medical damages should be valued in litigation and whether the bill favors defendants by tying recoverable amounts to insurance reimbursement rates and government fee schedules rather than billed charges or market rates. Plaintiffs’ attorneys may object to the use of Medicare/Medicaid benchmarks, especially for uninsured claimants or those treated under letters of protection, while defense կողմs may support the bill as a way to curb speculative or inflated claims. The treatment of letter-of-protection arrangements and third-party assignments is another likely flashpoint because it affects how unpaid medical bills are presented to juries and courts.